Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.79 (
hormone-sensitive lipase
)
2,163
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Broiler adipocytes in culture were used to determine whether prolonged preincubation with an antilipolytic hormone,
pancreatic polypeptide
, enhances lipolysis by inducing desensitization of lipolysis inhibition. Preincubation of broiler adipocytes with
pancreatic polypeptide
resulted in a dose-response and time-dependent enhancement (P < .05) of basal and glucagon-stimulated lipolysis. Lipolysis was enhanced at 4 and 24 h but not at .5 h of pretreatment. Acute inhibition of basal lipolysis was unaffected by long-term (24 h) exposure of adipocytes to a maximally effective dose (12 nM) of
pancreatic polypeptide
. Thus, desensitization of lipolysis inhibition cannot explain the enhanced lipolysis from
pancreatic polypeptide
-treated adipocytes. However, preincubation with 12 nM
pancreatic polypeptide
for 24 h reduced (P < .05)
pancreatic polypeptide
and somatostatin inhibition of lipolysis stimulated by glucagon. Moreover, basal lipolysis and submaximal lipolysis were enhanced to a similar extent (27 vs 29 nmol/h) but to a greater (P < .05) extent (27 vs 13 nmol/h) than maximal lipolysis when adipocytes were exposed to 12 nM
pancreatic polypeptide
for 24 h. These results suggest that the enhanced lipolysis induced by prolonged exposure of adipocytes to
pancreatic polypeptide
resulted from increased activity of
hormone-sensitive lipase
and activators of this enzyme and not from attenuation of lipolysis inhibition.
...
PMID:Enhanced lipolysis from broiler adipocytes pretreated with pancreatic polypeptide. 822 63